Notably, it has recently been demonstrated that H3K36me3-deficient cancers can be selectively targeted by a WEE1 inhibitor (AZD1775) (ref. 43), which might therefore constitute a new therapeutic option. The gene discussed is WEE1; the disease is cancer.